

22 **Abstract**

23 **Background:** Mendelian randomization (MR) studies suggest a causal effect of iron (Fe) status
24 on cardiovascular disease (CVD) risk, but it is unknown if these associations are confounded by
25 pleiotropic effects of the instrumental variables (IV) on CVD risk factors. We aimed to investigate
26 the effect of Fe status on CVD risk controlling for CVD risk factors.

27 **Methods:** Fe biomarker IVs (total Fe binding capacity (TIBC, $n=208,422$), transferrin saturation
28 (TSAT, $n=198,516$), serum Fe (SI, $n=236,612$), ferritin ($n=257,953$)) were selected from a
29 European GWAS meta-analysis. We performed two-sample univariate (UV) MR of each Fe trait
30 on CVD outcomes (all-cause ischemic stroke (IS), cardioembolic IS (CES), large artery IS (LAS),
31 small vessel IS (SVS), and coronary heart disease (CHD)) from MEGASTROKE ($n=440,328$) and
32 CARDIoGRAMplusC4D ($n=183,305$). We then implemented multivariate (MV) MR conditioning
33 on six CVD risk factors from independent European samples to evaluate their potential
34 confounding and/or mediating effects on the observed Fe-CVD associations.

35 **Results:** With UVMR analyses, we found higher genetically predicted Fe status to be associated
36 with a greater risk of CES (TSAT: OR 1.17 [95%CI 1.03, 1.33], SI: OR 1.21 [95%CI 1.02, 1.44];
37 TIBC: OR 0.81 [95%CI 0.69, 0.94]). The detrimental effects of Fe status on CES risk remained
38 unaffected when adjusting for CVD risk factors (all $P<0.05$). Additionally, we found diastolic
39 blood pressure (DBP) to mediate between 7.1-8.8% of the total effect of Fe status on CES
40 incidence. While UVMR initially suggested a protective effect of Fe status on LAS and CHD,
41 MVMR analyses factoring CVD risk factors revealed a complete annulment of this perceived
42 protective effect (all $P>0.05$).

43 **Discussion:** Higher Fe status was associated with a greater risk of CES independent of CVD risk
44 factors, and this effect was partly mediated by DBP. These findings support a role of Fe status as
45 a modifiable risk factor for CES.

46

47 **Key words:** Mendelian randomization, iron status, ischemic stroke, cardioembolic stroke risk

48 **Abbreviations:** AF, atrial fibrillation; Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; BMI,
49 body mass index; CARDIoGRAMplusC4D, Coronary ARtery Disease Genome wide Replication
50 and Meta-analysis plus The Coronary Artery Disease Genetics; CES, cardioembolic ischemic
51 stroke; CHD, coronary heart disease; CVD, cardiovascular disease; DBDS, Danish Blood Donor
52 Study; DBP, diastolic blood pressure;; Fe, iron; HDL, high density lipoprotein cholesterol; HUNT,
53 Trøndelag Health Study; IL-6, interleukin-6; IS, all-cause ischemic stroke; IV, instrumental
54 variable; IVW, inverse variance weighted; LAS, large artery atherosclerosis ischemic stroke; LDL,
55 low density lipoprotein cholesterol; MGI, Michigan Genomics Initiative; MR, Mendelian
56 randomization; MR-PRESSO, Mendelian randomization pleiotropy residual sum and outlier test;
57 MVMR, multivariate Mendelian randomization; NTBI, non-transferrin bound iron; SBP, systolic
58 blood pressure; SVS, small vessel ischemic stroke; TC, total cholesterol; TG, triglycerides; TIBC,
59 total iron binding capacity; TSAT, transferrin saturation; UKBB, UK Biobank.

60

61

62

63

64

65 **Introduction**

66 Iron (Fe) is an essential nutrient needed to support many biological processes. Both
67 extremes of Fe status have been associated with adverse cardiovascular outcomes. Iron deficiency
68 is the most prevalent micronutrient deficiency worldwide and is associated with significant
69 comorbidities affecting 70% of patients with heart failure (1), whereas Fe overload is implicated
70 in numerous cardiometabolic diseases (2). When circulating Fe exceeds the transport carrying
71 capacity of transferrin, Fe begins to circulate free, generating a toxic Fe species known as non-
72 transferrin bound Fe (NTBI). Cardiac, pancreatic, and hepatic cells all internalize NTBI via
73 different mechanisms (3, 4). Cellular uptake of NTBI increases the intracellular labile Fe pool
74 resulting in generation of reactive oxygen species and subsequent oxidative tissue damage (5).
75 Excess Fe in cardiomyocytes has been shown to induce ferroptosis, a form of regulated cell death
76 driven by Fe-dependent lipid peroxidation that is linked to cardiovascular disease (CVD) (6).

77 Although a link between Fe overload and CVD risk was proposed over 40 years ago (7),
78 epidemiological data to date have shown conflicting results. Clinical studies have reported
79 associations between atherosclerosis and increased serum Fe (8) or serum ferritin (9-13)
80 concentrations. Consistent with these observations, some studies demonstrated an association
81 between Fe depletion, either by Fe chelation therapy (14) or blood donation (15-17), and a
82 decreased risk of CVD. Conversely, other cross-sectional (18, 19) and longitudinal (20) studies
83 have reported a lack of an association. Most studies evaluating these relationships to date have
84 been conducted in populations with a relatively high prevalence of chronic diseases. As a result, it
85 remains uncertain if the observed variability in Fe status contributes to the onset of these diseases
86 or is a consequence of the diseases themselves, particularly since many commonly used Fe status
87 biomarkers (e.g., ferritin) can be elevated in response to inflammation.

88 Mendelian randomization (MR) is a statistical tool that uses genetic variation to explore
89 causal effects of a risk factor on a health outcome in the presence of unknown confounders under
90 three key assumptions: the genetic instruments selected as instrumental variables (IVs) must 1)
91 reliably predict the exposure, 2) only be associated with the outcome through its association with
92 the exposure, and 3) not be associated with confounders of the exposure-outcome association
93 (**Figure S1**). To date, few MR studies evaluating the effects of Fe status on CVD risk have been
94 published and these have found higher genetically predicted Fe status to be associated with a
95 decreased risk of atherosclerotic disease (21-23) and hypercholesteremia (24) and an increased
96 risk of ischemic stroke (IS) (25) and venous thromboembolism (VTE) (22). These MR studies
97 used three genetic variants in Fe-regulatory genes as IVs selected from a European genome-wide
98 association study (GWAS) of Fe biomarkers in < 50,000 individuals (26). However, the latest
99 GWAS of Fe status biomarkers has reached a sample size of up to 257,953 and increased the
100 number of genome-wide significant loci from 11 to 123 (27). Additionally, the IVs used in
101 published studies do not satisfy all MR assumptions as these have been reported to have genome-
102 wide significant associations with known confounders, including cholesterol, blood pressure, and
103 body mass index (BMI). Consequently, it is unknown if the reported associations are confounded
104 by pleiotropic effects of the IVs on CVD risk factors.

105 In depth analyses using the recently discovered genome-wide significant loci of Fe status
106 as IVs are needed to obtain reliable effect estimates of Fe status on CVD risk. Our aim was to
107 investigate the associations between genetically predicted Fe status and risk of ischemic stroke
108 (IS) and coronary heart disease (CHD) by employing an MR framework that controls for CVD
109 risk factors. A secondary aim was to investigate the pathways by which Fe status influences CVD
110 risk utilizing mediation analyses.

111 **Methods**

112 The work presented was performed using publicly available summary-level data from
113 published GWAS. All analyses were conducted using R version 4.2.2 (The R Foundation for
114 Statistical Computing). Results are reported per STROBE-MR recommendations (**Table S1**).

115 **Exposure data source**

116 Summary-level data were obtained from the largest Fe GWAS available to date, which
117 consisted of a meta-analysis of GWAS of six European populations (DeCODE, INTERNAL,
118 SardiNIA, Danish Blood Donor Study (DBDS), Trøndelag Health Study (HUNT), and Michigan
119 Genomics Initiative (MGI), for four Fe status biomarkers (serum Fe (SI), transferrin saturation
120 (TSAT), serum ferritin (SF), and total Fe binding capacity (TIBC)) (27) (**Table 1**). Descriptive
121 characteristics of the populations studied, the biomarker quantification methods utilized, and the
122 data sources are outlined in **Table S2**. The physiological significance of the Fe status indicators is
123 described in **Table S3**.

124

125 **Outcome data sources**

126 Detailed information on the outcome data sources used in this study are shown in **Table 1**
127 and **Table S4**.

128

129 *Cardiovascular disease risk factors*

130 Known CVD risk factors were selected to 1) investigate the causal effect of Fe on the risk
131 factor using two-sample univariate MR and 2) to investigate the confounding and/or mediating

132 effects of the significant risk factors on the associations of genetically predicted Fe status and CVD
133 using multivariate MR (MVMR). The risk factors selected were blood lipids (high density
134 lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), total cholesterol (TC),
135 triglycerides (TG), apolipoprotein A (Apo-A), apolipoprotein B (Apo-B), blood pressure
136 (diastolic blood pressure (DBP) and systolic blood pressure (SBP)), body mass index (BMI), and
137 an inflammatory marker (interleukin-6 (IL-6)). Summary statistics for blood lipids, blood pressure
138 outcomes and BMI were obtained from the UK Biobank and GWAS data for IL-6 were from a
139 meta-analysis of eleven independent European cohorts (28).

140 *Cardiovascular diseases*

141 CHD, all-cause IS, and IS subtypes were selected as primary CVD outcomes. CHD
142 summary statistics data were obtained from the CARDIoGRAMplusC4D (Coronary ARtery
143 Disease Genome wide Replication and Meta-analysis (CARDIoGRAM) plus The Coronary Artery
144 Disease (C4D) Genetics) 1000-Genomes GWAS meta-analysis (29), which consisted of a GWAS
145 meta-analysis of CHD in forty-eight multi-ethnic populations. Of the total sample size, 76% of the
146 participants included were of European descent. Summary-level data for IS and IS subtypes
147 (cardioembolic (CES), large artery atherosclerosis (LAS), small-vessel (SVS)) were obtained from
148 a GWAS meta-analysis in seventeen European populations led by the MEGASTROKE consortium
149 (30). We were unable to rule out potential sample overlap between the MEGASTROKE and the
150 exposure data because both GWAS meta-analyses involved individuals from deCODE. To
151 mitigate the risk of type I error (31), we tested an additional outcome closely related to IS, atrial
152 fibrillation (AF), to validate our findings. Summary-level GWAS data for AF were obtained from
153 a GWAS meta-analysis of European consortiums including Atrial Fibrillation Genetics consortium
154 (AFGen) and the Broad AF study (32).

155 Instrumental variable selection

156 Independent SNPs ($r^2 < 0.001$) associated with each Fe trait at genome-wide significance
157 level ($P < 5 \times 10^{-8}$) were extracted from the Fe GWAS meta-analysis (27). Rare SNPs with a minor
158 allele frequency (MAF) $< 1\%$ in Europeans were excluded. SNPs defined as being ambiguous with
159 intermediate allele frequencies were removed. Additionally, to further minimize the potential for
160 pleiotropy, SNPs that had direction of effects that were not consistent with systemic Fe status were
161 removed (i.e., higher Fe status results in increased TSAT, serum Fe and ferritin, and decreased
162 TIBC). Lastly, SNPs that were not genotyped in the outcome dataset were replaced by proxy SNPs
163 if available or removed if no proxy SNP was found. Proxy SNPs were defined as a SNP in linkage
164 disequilibrium (LD; $r^2 > 0.8$) with the genetic instrument in a European reference population
165 (**Table S5**).

166 The strength and validity of the genetic instruments were evaluated by calculating the
167 variance in the Fe trait explained by a SNP (R^2) and the F -statistic. The R^2 for each SNP was
168 calculated using the equation $R^2 = 2\beta^2 \text{MAF} (1-\text{MAF})$, where β is the regression coefficient from
169 the SNP-Fe trait association from the GWAS, and MAF is the minor allele frequency for that SNP.
170 The F -statistic was calculated using the equation $F\text{-statistic} = (n-k-1/k)(R^2_{\text{instrument}} / 1 - R^2_{\text{instrument}})$,
171 where n is the population sample size, k is the number of SNPs in the instrument, and $R^2_{\text{instrument}}$ is
172 the sum of the R^2 for each SNP included in the instrument (33). We considered the MR standard
173 F -statistic > 10 to indicate adequate instrument strength (33). The SNPs selected as instrumental
174 variables and their respective R^2 and F -statistic are shown in **Table S5**. The $R^2_{\text{instrument}}$ and the F -
175 statistic of the instruments were calculated after data harmonization for all four Fe biomarkers for
176 each outcome evaluated as shown in **Table S6**.

177

178 **Mendelian randomization**

179 We developed a workflow combining variations of the MR method (**Figure 1**). Initial
180 analyses consisted of univariate MR analyses to identify major CVD risk factors that are
181 influenced by Fe traits (**Figure 1**; step 1a) and to evaluate the total effect of Fe traits on CVD
182 outcomes (**Figure 1**; step 1b). Variables meeting the selection criteria were carried over to step 2,
183 which consisted of MVMR analyses to determine the direct effects of Fe traits on CVD outcomes
184 conditioning on major CVD risk factors (**Figure 1**; step 2). Lastly, CVD risk factors satisfying the
185 selection criteria were carried over to step 3, where these were evaluated as mediators of the Fe
186 trait-CVD associations and the indirect effects of Fe traits on CVD were calculated (**Figure 1**; step
187 3). The detailed MR models implemented, and the variables tested at each step are presented in
188 **Figure S2**.

189 *Univariate Mendelian randomization*

190 We performed three main MR estimations for each exposure-outcome test, which included
191 the inverse variance weighted (IVW) method under multiplicative random effects (34), the MR-
192 Egger method, and the weighted median (WM) method. The IVW method requires either all SNPs
193 used as IVs to be valid instruments or that there is balanced horizontal pleiotropy, whereas the
194 MR-Egger and weighted median are more robust to bias introduced by weak IVs; the MR-Egger
195 is less susceptible to bias introduced by horizontal pleiotropy (35) and the weighted median (WM)
196 provides an unbiased estimate if <50% of the SNPs used as IVs present evidence of pleiotropy
197 (36). When significant evidence of pleiotropy was detected (described below under “sensitivity
198 analyses”), the WM and MR-Egger estimates were prioritized for interpretation of results.
199 Univariate MR analyses were performed using the ‘*TwoSampleMR*’ R package (37). MR estimates
200 are presented as the β and standard error (SE) per 1-SD unit change in the Fe status biomarker for

201 continuous outcomes, and as odds ratio (OR) and 95% CI per 1-SD unit change in the Fe status
202 biomarker for dichotomous outcomes.

203 *Multivariate Mendelian randomization*

204 MVMR is an extension of the two-sample univariate MR method that can be employed to
205 estimate the effect of an exposure on an outcome while controlling for confounders (38). We
206 performed MVMR on CVD outcomes meeting our prioritization criteria conditioning on one CVD
207 risk factor at a time. MVMR estimates were calculated using the IVW method and all MVMR
208 analyses were performed using the ‘*MVMR*’ R packages (39, 40), which extend the typical MR
209 main and sensitivity tests (IVW and Cochran’s Q) to MVMR analyses. The conditional F -statistic,
210 which accounts for the association between each SNP with other exposures included in the
211 estimation, was calculated to assess instrument strength.

212 *Mediation analysis*

213 Mediation analyses were conducted to assess the mechanisms by which Fe status
214 influences CVD outcomes. Effect estimates obtained from the univariate MR (total effects of Fe
215 on CVD (**Figure 1**; step1a) and CVD risk factor (**Figure 1**; step1b)) and MVMR (direct effects
216 of Fe on CVD conditioning on a CVD risk factor (**Figure 1**; step 2)) were used to calculate the
217 indirect effects of Fe status on a CVD outcome using the product of coefficients method (41). This
218 method was selected as the outcomes evaluated are considered rare with a prevalence <10% (42).
219 The SE and 95% CI were calculated using the Delta method (43). The percent of effect mediated
220 by a CVD risk factor was calculated as the estimated indirect effect divided by the total effect from
221 univariate MR x 100 (43). Mediation estimates are presented as the log odds ratio, SE and 95%
222 CI.

223

224 **Sensitivity Analyses**

225 Pleiotropy refers to a phenomenon in which a variant has causal effects on more than one
226 phenotype. In the context of MR, significant bias is introduced when there is evidence of pleiotropy
227 within the genetic instruments (i.e., if the MR assumption 3 is not met). We evaluated the presence
228 of directional pleiotropy using the Cochran's Q statistic and the MR-Egger intercept for the
229 univariate MR analyses. Additionally, we performed the MR pleiotropy residual sum and outlier
230 (MR-PRESSO) test using the '*MRPRESSO*' package in R, which identifies pleiotropic outliers
231 (44). When outliers were detected, the MR-PRESSO outlier-corrected effect estimates were
232 calculated and presented. For MVMR analyses, heterogeneity was evaluated with the Q_A statistic.
233 Lastly, we evaluated potential pleiotropic effects of the SNPs used as genetic instruments using
234 the online tools LDtrait (45) and PhenoScanner (46, 47). We searched for Fe-associated SNPs or
235 SNPs in LD ($r^2 > 0.8$) with these SNPs that had genome-wide significant associations ($P < 5 \times 10^{-8}$)
236 with CVD risk factors (such as blood lipids, BMI, and blood pressure) or with CVD outcomes
237 (such as CHD, IS, and AF) (**Table S5**). SNPs previously reported to have a genome-wide
238 significant association with a CVD outcome were excluded in sensitivity analyses for MVMR.

239

240 **Power Calculations**

241 Statistical power for binary outcomes (i.e., CVD outcomes) was calculated using the online
242 tool for power calculations for MR (48) and for continuous outcomes (i.e., CVD risk factors) using
243 published methods and R code (49). Based on our strongest instrumental variable with an R^2 of
244 0.055 at an $\alpha=0.05$, our analyses were sufficiently powered (>80%) to detect an odds ratio ≤ 0.94

245 or ≥ 1.06 for CHD, ≤ 0.93 or ≥ 1.07 for IS, ≤ 0.81 or ≥ 1.19 for CES, ≤ 0.83 or ≥ 1.17 for LAS, \leq
246 0.85 or ≥ 1.15 for SVS, and ≤ 0.94 or ≥ 1.06 for AF using two-sample MR. Detailed power
247 calculations for each Fe exposure-outcome combination are shown in **Table S7**.

248

249 **Results**

250 **Univariate Mendelian randomization**

251 We used common independent SNPs (**Table S5**) explaining 5.5%, 3.9%, 3.2% and 1.5%
252 of the variance in TSAT, TIBC, serum Fe and ferritin, respectively. Instrument F -statistic for all
253 four Fe biomarkers ranged from 109 to 1024 after harmonization of exposure and outcome data
254 (**Table S6**).

255 The MR estimates for the effects of genetically predicted Fe status on CVD risk factors are
256 shown in **Tables S8-S11**. For the Fe-blood lipids, Fe-BP, and Fe-BMI analyses the WM and MR-
257 Egger estimates were prioritized for interpretation of results as the Cochran's Q statistic
258 demonstrated evidence of pleiotropy between genetic instruments ($P < 0.05$); little to no evidence
259 of pleiotropy was evident from the MR-Egger intercept test ($P > 0.05$). For the Fe-IL-6 analyses,
260 no evidence of heterogeneity was observed ($P > 0.05$ for the Cochran's Q statistic and MR-Egger
261 intercept); thus, the IVW MR estimates were taken into consideration.

262 Higher genetically predicted TSAT, indicative of higher Fe status, was associated with
263 lower LDL cholesterol (WM: $\beta = -0.11$; SE = 0.01, $P = 3.9 \times 10^{-14}$), TC (WM: $\beta = -0.10$; SE = 0.02,
264 $P = 5.3 \times 10^{-10}$), and Apo-B (WM: $\beta = -0.10$; SE = 0.01, $P = 9.2 \times 10^{-13}$), and with higher Apo-A
265 (WM: $\beta = 0.02$; SE = 0.009, $P = 0.007$), and triglycerides (WM: $\beta = 0.03$; SE = 0.009, $P = 0.002$).
266 No evidence of an effect was observed for HDL (WM: $P = 0.5$), BMI (WM: $P = 0.1$), or IL-6

267 (IVW: $P = 0.2$). With respect to blood pressure outcomes evaluated, higher genetically predicted
268 TSAT was associated with higher DBP (WM: $\beta = 0.06$; SE = 0.01, $P = 1.22 \times 10^{-9}$), but was not
269 associated with SBP (WM: $P = 0.7$). Consistent effects on all CVD risk factors except for BMI
270 were observed when serum Fe and TIBC were evaluated as exposures (**Tables S8-S10**). While
271 genetically predicted TSAT and serum Fe were not associated with BMI, higher TIBC (indicative
272 of lower Fe status) was associated with a higher BMI (WM: $\beta = 0.03$; SE = 0.009, $P = 0.01$).
273 Overall, the direction of effects for ferritin as the exposure were consistent with the other Fe
274 biomarkers, but weaker associations were observed due to the lower statistical power of its IVs
275 (**Table S11**).

276 The MR-PRESSO analyses identified possible pleiotropic outliers for all CVD risk factors
277 evaluated except for IL-6 (**Tables S8-S11**). For analyses of TIBC as the exposure, no change was
278 observed with respect to significance and direction of effect after implementation of the outlier
279 correction (**Table S10**), but few differences were observed for analyses of TSAT and serum Fe as
280 the exposures (**Tables S8 and S9**). The MR-PRESSO outlier-corrected estimates suggested a
281 significant association of lower genetically predicted TSAT (WM: $\beta = -0.03$; SE = 0.009, $P = 0.01$)
282 and serum Fe (WM: $\beta = -0.04$; SE = 0.01, $P = 0.01$) with a higher BMI, but a null effect on the
283 blood lipids and blood pressure (**Tables S8 and S9**). Caution should be taken when interpreting
284 these estimates as the lack of an effect may have resulted from a weak instrument and a lower
285 statistical power after the removal of SNPs.

286 The MR OR per 1-SD unit increase in TSAT, serum Fe, TIBC and ferritin are presented in
287 **Table 2**. Univariate MR analyses showed evidence for a causal effect of higher Fe status on CVD
288 outcomes, but the direction of effect differed by outcome. Higher genetically predicted Fe status,
289 as evidenced by a higher TSAT, serum Fe, or lower TIBC, was associated with a greater risk of

290 CES, a lower risk of CHD, and was not associated with all-cause IS or SVS. Lower genetically
291 predicted TIBC, indicative of higher Fe status, was associated with a lower risk of LAS. Using
292 MR-PRESSO, outliers were detected for the associations of TSAT and TIBC with CHD.
293 Nonetheless, outlier-corrected estimates and *P*-values were in agreement with the other MR
294 methods (**Table 2**). Analyses for AF appeared to have significant heterogeneity (*P*-value for
295 Cochran's *Q* statistic < 0.05); thus, WM and MR-PRESSO were prioritized for interpretation.
296 Consistent with the detrimental effects of higher Fe status on CES, we found greater genetically
297 predicted Fe status, as evidenced by higher TSAT and serum Fe and lower TIBC, to be associated
298 with an increased risk of AF (**Table 2**).

299

300 **Multivariate Mendelian randomization**

301 We carried out MVMR utilizing selected variables meeting the prioritization criteria from
302 the univariate MR analyses. Because the power of the genetic instrument is greatly reduced when
303 conditioning on additional exposures using MVMR, we excluded ferritin from the MVMR
304 analyses given that the genetic instruments for ferritin only explain a small proportion of its
305 variance. For all MVMR models of TSAT, serum Fe or TIBC as exposures, the conditional *F*-
306 statistic was > 10, demonstrating that weak instrumental bias is unlikely to be present (**Tables S12-**
307 **S14**).

308 MVMR analyses provided evidence for a causal effect of higher Fe status on CES after
309 conditioning on CVD risk factors, and this observation was consistent across TSAT, serum Fe and
310 TIBC as shown in **Figure 2**. The protective effect of higher Fe status on CHD and LAS observed
311 in the univariate MR analyses was entirely nullified after controlling for blood lipids (**Figure 3**).

312 The confounding effects of BMI on the analyses were not consistent throughout the three Fe status
313 exposures. The protective effect of lower TIBC and higher TSAT on CHD remained significant
314 when conditioning for BMI. However, the presumed effects serum Fe on CHD disappeared when
315 conditioning on BMI (**Figure 3**).

316 Evaluation of heterogeneity using the Q_A statistic showed little to no heterogeneity in the
317 analyses evaluating CES as the outcome (P -heterogeneity > 0.05) (**Table S12**). Substantial
318 heterogeneity was noted in the MVMR analyses for CHD and LAS (P -heterogeneity < 0.05)
319 (**Tables S13 and S14**). From our LDlink and PhenoScanner searches we identified two SNPs that
320 have been shown to be associated at genome-wide significance level with coronary artery disease
321 and one SNP with venous thromboembolism (**Table S5**). Additional sensitivity analyses excluding
322 these three SNPs did not affect the results, thus, demonstrating robustness of findings (**Table S15**).

323

324 **Mediation analyses**

325 We conducted mediation analyses to evaluate the indirect effect of TSAT, serum Fe and
326 TIBC on CES via selected mediators (DBP, BMI, LDL, TC, TG, Apo-B, Apo-A) using effect
327 estimates derived from univariate MR and MVMR analyses. Significant mediation of the Fe status-
328 CES relationship via DBP was observed consistently across the three Fe status exposures (**Table**
329 **3**). The estimated percent of the total effect of Fe status on CES mediated by DBP was 7.1, 8.0 and
330 8.8 % for serum Fe, TIBC and TSAT, respectively. The magnitude of mediation observed for BMI
331 and blood lipid fractions evaluated was substantially lower (0-2 %) and was not statistically
332 significant based on the wider 95% CI that crossed the null. Detailed calculations are shown in
333 **Table S16**.

334

335 **Discussion**

336 To our knowledge, this is the first study to implement MVMR to evaluate the effects of Fe
337 status on CVD outcomes while adjusting for potential confounding variables. Our findings
338 revealed a noteworthy association between higher genetically predicted Fe status and an increased
339 risk of CES that is independent of major CVD risk factors, including blood lipids, DBP, and BMI.
340 Further employing mediation analyses, we found that DBP partially mediates the effect of Fe status
341 on CES. Interestingly, while univariate MR initially suggested a protective effect of higher Fe
342 status on CHD and LAS, our comprehensive MVMR analyses factoring CVD risk factors, revealed
343 a complete annulment of this perceived protective effect.

344 Our analyses using univariate two-sample MR to evaluate the effects of Fe status on CVD
345 outcomes were consistent with previous MR studies based on smaller-scale GWAS of Fe traits
346 (21-25). First, we replicated the observed protective effect of higher Fe levels on atherosclerotic
347 CVD outcomes, including CHD and LAS. We also replicated the analyses pertaining to CES
348 indicating an adverse effect of higher Fe status on this outcome. Lastly, consistent with a previous
349 MR study (50), we found an association between higher genetically predicted Fe status with an
350 increased risk of AF. This finding holds particular relevance as AF is the most significant risk
351 factor for CES (51), aligning consistently with the observed effects of Fe levels on CES.

352 We further evaluated the causal effects of Fe status on major CVD risk factors using
353 univariate MR. We found, for the first time using causal inference methods, an association between
354 higher genetically predicted Fe status and higher DBP. The lack on an association between Fe
355 status and SBP may have resulted from a low statistical power as suggested by our power

356 calculations. Few studies to date have evaluated the potential effects of Fe status on blood pressure.
357 A phenome-wide association study implementing MR found higher Fe status to increase risk of
358 hypertension at a nominal significance level (25). In agreement, observational studies have shown
359 that higher serum ferritin is associated with an increased risk of hypertension in adult men (52,
360 53), and serum Fe was found to be positively associated with an increased risk of hypertension
361 during pregnancy (54). We then evaluated the causal effects of Fe status on BMI and found lower
362 Fe status, as evidenced by higher TIBC, to be associated with a higher BMI. This is consistent
363 with observational studies reporting a relationship between obesity and Fe deficiency, which is
364 believed to stem from an interplay between Fe regulation and adiposity (55). With respect to blood
365 lipids, higher genetically predicted Fe status was associated with better lipid profiles as evidenced
366 by lower LDL, TC, and Apo-B and higher Apo-A concentrations. While these results are in
367 agreement with a previous MR study showing an association between genetically predicted higher
368 serum Fe and lower LDL and TC levels, and a decreased risk of hypercholesteremia and
369 hyperlipidemia (24, 56), we found evidence suggestive of substantial pleiotropy in the analyses.
370 The observed heterogeneity likely results from the significant overlap between Fe and lipid IVs as
371 evidenced by our sensitivity analyses showing a lack of an association after removal of pleiotropic
372 outliers. Lastly, genetically predicted Fe status was not associated with IL-6 in our analyses.
373 Nonetheless, future MR studies should evaluate this relationship in the opposite direction (i.e., the
374 effects of IL-6 on Fe status) as it is well-established that inflammation, particularly via IL-6, is a
375 negative regulator of Fe status (57).

376 Although the results from univariate MR analyses carry important implications, a major
377 limitation is the potential bias introduced by pleiotropic effects of the genetic instruments as
378 several Fe-associated SNPs are strongly associated with major CVD risk factors. To overcome this

379 limitation, we performed MVMR analyses conditioning on selected CVD risk factors. Most
380 notably, with these analyses we found that the effects of Fe status on CES were unaffected by
381 adjustment for DBP, BMI, or blood lipids (LDL, TC, TG, Apo-B, Apo-A). This provides evidence
382 in support of a causal effect of higher Fe status on CES incidence that is independent of major
383 CVD risk factors. Available observational evidence evaluating the associations between Fe status
384 and risk of stroke is inconclusive as reviewed (25). However, these contrasting observations may
385 stem from differences between IS subtypes as evidenced by our opposing results when evaluating
386 IS by subtype. This highlights the importance of evaluating IS with stratification by subtype.

387 We hypothesized that Fe's detrimental effect on CES is at least partially mediated by CVD
388 risk factors evaluated in this study. Using mediation analyses, we identified DBP as potential
389 pathway through which elevated Fe levels contribute to an increased risk of CES. Accumulation
390 of excess Fe, such that it increases the labile Fe pool, results in the production of highly reactive
391 species, consequently inducing oxidative stress. It is known that oxidative stress contributes to the
392 pathogenesis of hypertension (58), a common vascular risk factor for CES. Thus, Fe-induced
393 oxidative stress may be a mechanism by which higher Fe levels influence CES development
394 directly and indirectly via its effects on blood pressure. Blood lipids did not appear to play a
395 mediating role in the relationship between Fe status and CES, suggesting that the effect of higher
396 Fe status on CES risk is unlikely to operate via the blood lipid fractions evaluated.

397 In contrast to the robust evidence observed for CES, the apparent protective effect of higher
398 Fe status on CHD and LAS was diminished after adjustment for CVD risk factors using MVMR,
399 suggesting a lack of a direct effect of Fe status on CHD and LAS when accounting for major CVD
400 risk factors. Of note, significant heterogeneity was observed in these analyses, particularly when

401 evaluating CHD as the outcome. Thus, more investigations are needed to characterize the complex
402 interplay between Fe, atherosclerosis, and subsequent CVD outcomes.

403 Our study has limitations that warrant attention. First, due to our reliance on summary-
404 rather than individual-level data, we were unable to explore potential sex-based differences in the
405 relationships between Fe status and CVD risk factors. This is particularly relevant to Fe and CVD
406 as both Fe status markers and risk of CVD differ significantly between males and females. To our
407 knowledge, there are no sex-stratified summary-level GWAS data from either Fe status or CVD
408 that are publicly available and adequately powered to address these questions. However, it remains
409 crucial to replicate these analyses in males and females separately. Furthermore, while we selected
410 the best available outcome datasets that closely matched the population in the exposure dataset
411 and that adjusted for similar covariates, the possibility of population stratification cannot be ruled
412 out. Additionally, since our study was based in European populations, we are unable to extrapolate
413 our results to non-European populations. Evaluating this question in other populations is of
414 pressing need as risk of excess body Fe accumulation differs between populations, with individuals
415 of East Asian ancestry presenting the greatest body Fe burden (59). Another important
416 consideration is that MR methods estimate the lifetime effect of Fe status; thus, the magnitude of
417 the MR estimates may be greater in our study than what would be observed clinically. This
418 characteristic of MR holds implications for our study as Fe accumulation differs throughout life
419 stages. For instance, risk of Fe overload in females escalates post-menopause due to the cessation
420 of menses and the effect size of elevated Fe on disease development may differ accordingly. Lastly,
421 all MR approaches implemented in this study assume linear associations. However, there is a
422 possibility that the effect of Fe on some of the exposures evaluated is not linear, potentially
423 masking some effects.

424 In conclusion, our findings underscore the significance of Fe status as a novel modifiable
425 risk factor for CES. Additionally, when controlling for CVD risk factors, the presumed protective
426 effect of higher Fe status on atherosclerotic heart disease outcomes was negated. Future studies
427 are needed to evaluate possible sex and population differences in the effects of Fe status on CVD
428 risk. Lastly, given the inherent limitations of MR methods, additional studies are needed to confirm
429 then clinical utility of Fe status in predicting risk of CES.

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447 **Acknowledgements:** We thank the CARDIoGRAMplusC4D, MEGASTROKE, UK Biobank
448 investigators for making their data publicly available. The MEGASTROKE project received
449 funding from sources specified at <http://www.megastroke.org/acknowledgments.html>.

450 **Author's Contributions:** AB designed and conducted the research, analyzed and interpreted the
451 data, and wrote the manuscript; AGC, EKP and KOO interpreted the data and assisted with the
452 manuscript preparation.

453 **Data and Code Availability:** The GWAS summary-level data are publicly available for all
454 exposures and outcomes evaluated. The exposure summary-statistic can be found directly from the
455 original GWAS publication (27). Data on coronary artery disease have been contributed by
456 CARDIoGRAMplusC4D investigators. The UK Biobank, CARDIOGRAMplusC4D consortium,
457 MEGASTROKE, and IL-6 GWAS summary-level data are available in IEU OpenGWAS
458 (<https://gwas.mrcieu.ac.uk/>). The MR analysis code may be obtained from the corresponding
459 author upon reasonable request.

460 **Funding Sources:** This work was supported by the American Heart Association (23PRE1025636)
461 and the NIH National Institute of Diabetes and Digestive and Kidney Diseases (R01DK122216).
462 The funding sources were not involved in the preparation of the manuscript.

463 **Disclosures:** None (AB, AGC, EKP, KOO).

References

1. Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, et al. Criteria for Iron Deficiency in Patients With Heart Failure. *J Am Coll Cardiol*. 2022;79(4):341-51.
2. Fernández-Real JM, Manco M. Effects of iron overload on chronic metabolic diseases. *Lancet Diabetes Endocrinol*. 2014;2(6):513-26.
3. Jenkitkasemwong S, Wang CY, Coffey R, Zhang W, Chan A, Biel T, et al. SLC39A14 Is Required for the Development of Hepatocellular Iron Overload in Murine Models of Hereditary Hemochromatosis. *Cell Metab*. 2015;22(1):138-50.
4. Oudit GY, Sun H, Trivieri MG, Koch SE, Dawood F, Ackerley C, et al. L-type Ca²⁺ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy. *Nat Med*. 2003;9(9):1187-94.
5. Fang X, Ardehali H, Min J, Wang F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. *Nat Rev Cardiol*. 2022:1-17.
6. Wu X, Li Y, Zhang S, Zhou X. Ferroptosis as a novel therapeutic target for cardiovascular disease. *Theranostics*. 2021;11(7):3052-9.
7. Sullivan JL. Iron and the sex difference in heart disease risk. *Lancet*. 1981;1(8233):1293-4.
8. Bagheri B, Shokrzadeh M, Mokhberi V, Azizi S, Khalilian A, Akbari N, et al. Association between Serum Iron and the Severity of Coronary Artery Disease. *Int Cardiovasc Res J*. 2013;7(3):95-8.
9. Salonen JT, Nyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. *Circulation*. 1992;86(3):803-11.
10. Ahluwalia N, Genoux A, Ferrieres J, Perret B, Carayol M, Drouet L, et al. Iron status is associated with carotid atherosclerotic plaques in middle-aged adults. *J Nutr*. 2010;140(4):812-6.
11. Kiechl S, Willeit J, Egger G, Poewe W, Oberhollenzer F. Body iron stores and the risk of carotid atherosclerosis: prospective results from the Bruneck study. *Circulation*. 1997;96(10):3300-7.
12. Menke A, Fernández-Real JM, Muntner P, Guallar E. The association of biomarkers of iron status with peripheral arterial disease in US adults. *BMC Cardiovasc Disord*. 2009;9:34.
13. Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD. Ferritin is independently associated with the presence of coronary artery calcium in 12,033 men. *Arterioscler Thromb Vasc Biol*. 2012;32(10):2525-30.
14. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF, Jr., et al. Iron chelation improves endothelial function in patients with coronary artery disease. *Circulation*. 2001;103(23):2799-804.

15. Salonen JT, Tuomainen TP, Salonen R, Lakka TA, Nyssönen K. Donation of blood is associated with reduced risk of myocardial infarction. The Kuopio Ischaemic Heart Disease Risk Factor Study. *Am J Epidemiol*. 1998;148(5):445-51.
16. Meyers DG, Jensen KC, Menitove JE. A historical cohort study of the effect of lowering body iron through blood donation on incident cardiac events. *Transfusion*. 2002;42(9):1135-9.
17. Houshyar KS, Lüdtke R, Dobos GJ, Kalus U, Broecker-Preuss M, Rampp T, et al. Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. *BMC Med*. 2012;10:54.
18. Bozzini C, Girelli D, Tinazzi E, Olivieri O, Stranieri C, Bassi A, et al. Biochemical and genetic markers of iron status and the risk of coronary artery disease: an angiography-based study. *Clin Chem*. 2002;48(4):622-8.
19. Yunker LM, Parboosingh JS, Conradson HE, Faris P, Bridge PJ, Buithieu J, et al. The effect of iron status on vascular health. *Vasc Med*. 2006;11(2):85-91.
20. Galan P, Noisette N, Estaquio C, Czernichow S, Mennen L, Renversez JC, et al. Serum ferritin, cardiovascular risk factors and ischaemic heart diseases: a prospective analysis in the SU.VI.MAX (SUpplementation en VItamines et Minéraux AntioXydants) cohort. *Public Health Nutr*. 2006;9(1):70-4.
21. Gill D, Del Greco MF, Walker AP, Srai SKS, Laffan MA, Minelli C. The Effect of Iron Status on Risk of Coronary Artery Disease: A Mendelian Randomization Study-Brief Report. *Arterioscler Thromb Vasc Biol*. 2017;37(9):1788-92.
22. Gill D, Brewer CF, Monori G, Trégouët DA, Franceschini N, Giambartolomei C, et al. Effects of Genetically Determined Iron Status on Risk of Venous Thromboembolism and Carotid Atherosclerotic Disease: A Mendelian Randomization Study. *J Am Heart Assoc*. 2019;8(15):e012994.
23. Yang F, Bao Q, Wang Z, Ma M, Shen J, Ye F, et al. Sex-Specific Genetically Predicted Iron Status in relation to 12 Vascular Diseases: A Mendelian Randomization Study in the UK Biobank. *Biomed Res Int*. 2020;2020:6246041.
24. Gill D, Benyamin B, Moore LSP, Monori G, Zhou A, Koskeridis F, et al. Associations of genetically determined iron status across the phenome: A mendelian randomization study. *PLoS Med*. 2019;16(6):e1002833.
25. Gill D, Monori G, Tzoulaki I, Dehghan A. Iron Status and Risk of Stroke. *Stroke*. 2018;49(12):2815-21.
26. Benyamin B, Esko T, Ried JS, Radhakrishnan A, Vermeulen SH, Traglia M, et al. Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. *Nat Commun*. 2014;5:4926.
27. Moksnes MR, Graham SE, Wu KH, Hansen AF, Gagliano Taliun SA, Zhou W, et al. Genome-wide meta-analysis of iron status biomarkers and the effect of iron on all-cause mortality in HUNT. *Commun Biol*. 2022;5(1):591.

28. Folkersen L, Gustafsson S, Wang Q, Hansen DH, Hedman Å K, Schork A, et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. *Nat Metab.* 2020;2(10):1135-48.
29. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet.* 2015;47(10):1121-30.
30. Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet.* 2018;50(4):524-37.
31. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. *Genet Epidemiol.* 2016;40(7):597-608.
32. Roselli C, Chaffin MD, Weng LC, Aeschbacher S, Ahlberg G, Albert CM, et al. Multi-ethnic genome-wide association study for atrial fibrillation. *Nat Genet.* 2018;50(9):1225-33.
33. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies. *Int J Epidemiol.* 2011;40(3):755-64.
34. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for performing Mendelian randomization investigations: update for summer 2023. *Wellcome Open Res.* 2019;4:186.
35. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *Int J Epidemiol.* 2015;44(2):512-25.
36. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol.* 2016;40(4):304-14.
37. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. *Elife.* 2018;7.
38. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. *Int J Epidemiol.* 2019;48(3):713-27.
39. Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. *Stat Med.* 2021;40(25):5434-52.
40. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int J Epidemiol.* 2017;46(6):1734-9.
41. Sanderson E. Multivariable Mendelian Randomization and Mediation. *Cold Spring Harb Perspect Med.* 2021;11(2).
42. Carter RC, Georgieff MK, Ennis KM, Dodge NC, Wainwright H, Meintjes EM, et al. Prenatal alcohol-related alterations in maternal, placental, neonatal, and infant iron homeostasis. *Am J Clin Nutr.* 2021;114(3):1107-22.

43. Carter AR, Sanderson E, Hammerton G, Richmond RC, Davey Smith G, Heron J, et al. Mendelian randomisation for mediation analysis: current methods and challenges for implementation. *Eur J Epidemiol*. 2021;36(5):465-78.
44. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. *Nat Genet*. 2018;50(5):693-8.
45. Lin SH, Brown DW, Machiela MJ. LDtrait: An Online Tool for Identifying Published Phenotype Associations in Linkage Disequilibrium. *Cancer Res*. 2020;80(16):3443-6.
46. Staley JR, Blackshaw J, Kamat MA, Ellis S, Surendran P, Sun BB, et al. PhenoScanner: a database of human genotype-phenotype associations. *Bioinformatics*. 2016;32(20):3207-9.
47. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. *Bioinformatics*. 2019;35(22):4851-3.
48. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. *Int J Epidemiol*. 2013;42(5):1497-501.
49. Deng L, Zhang H, Yu K. Power calculation for the general two-sample Mendelian randomization analysis. *Genet Epidemiol*. 2020;44(3):290-9.
50. Wang T, Cheng J, Wang Y. Genetic support of a causal relationship between iron status and atrial fibrillation: a Mendelian randomization study. *Genes Nutr*. 2022;17(1):8.
51. Khurshid S, Trinquart L, Weng LC, Hulme OL, Guan W, Ko D, et al. Atrial Fibrillation Risk and Discrimination of Cardioembolic From Noncardioembolic Stroke. *Stroke*. 2020;51(5):1396-403.
52. Kim MK, Baek KH, Song KH, Kang MI, Choi JH, Bae JC, et al. Increased serum ferritin predicts the development of hypertension among middle-aged men. *Am J Hypertens*. 2012;25(4):492-7.
53. Lee DH, Kang SK, Choi WJ, Kwak KM, Kang D, Lee SH, et al. Association between serum ferritin and hypertension according to the working type in Korean men: the fifth Korean National Health and nutrition examination survey 2010-2012. *Ann Occup Environ Med*. 2018;30:40.
54. Song QY, Luo WP, Zhang CX. High serum iron level is associated with an increased risk of hypertensive disorders during pregnancy: a meta-analysis of observational studies. *Nutr Res*. 2015;35(12):1060-9.
55. Hilton C, Sabaratnam R, Drakesmith H, Karpe F. Iron, glucose and fat metabolism and obesity: an intertwined relationship. *Int J Obes (Lond)*. 2023;47(7):554-63.
56. Zhou J, Liu C, Francis M, Sun Y, Ryu MS, Grider A, et al. The Causal Effects of Blood Iron and Copper on Lipid Metabolism Diseases: Evidence from Phenome-Wide Mendelian Randomization Study. *Nutrients*. 2020;12(10).
57. Ganz T, Nemeth E. Hypoferremia of inflammation: Innate host defense against infections. *Blood Cells Mol Dis*. 2024;104:102777.

58. Griendling KK, Camargo LL, Rios FJ, Alves-Lopes R, Montezano AC, Touyz RM. Oxidative Stress and Hypertension. *Circ Res.* 2021;128(7):993-1020.
59. Kang W, Barad A, Clark AG, Wang Y, Lin X, Gu Z, et al. Ethnic Differences in Iron Status. *Adv Nutr.* 2021;12(5):1838-53.

Table 1. Summary of exposure and outcome genome-wide association studies (GWAS) datasets.

	Data Source	Source ID	Consortium	Variable type	Sample Size/ Cases/controls	Population	Sex	PMID	Year
Iron status									
TSAT	NTNU Open Research Data	10.18710/S9TJEL	HUNT, MGI, deCODE, INTERVAL	Continuous	198,516	EUR	M/F	35710628	2022
SI	NTNU Open Research Data	10.18710/S9TJEL	HUNT, MGI, deCODE, INTERVAL, SardinIA	Continuous	236,612	EUR	M/F	35710628	2022
TIBC	NTNU Open Research Data	0.18710/S9TJEL	HUNT, MGI, deCODE, INTERVAL, SardinIA	Continuous	208,422	EUR	M/F	35710628	2022
Ferritin	NTNU Open Research Data o	10.18710/S9TJEL	HUNT, MGI, deCODE, INTERVAL, DBDS	Continuous	257,953	EUR	M/F	35710628	2022
Cardiovascular Disease									
CHD	IEU OpenGWAS	ieu-a-7	CARDIoGRAM-plusCD4	Binary	60,801 / 123,504	Mixed (76% EUR)	M/F	26343387	2015
CES	IEU OpenGWAS	ebi-a-GCST006910	MEGASTROKE	Binary	7,193 / 406,111	EUR	M/F	29531354	2018
LAS	IEU OpenGWAS	ebi-a-GCST006907	MEGASTROKE	Binary	4,373 / 406,111	EUR	M/F	29531354	2018
SVS	IEU OpenGWAS	ebi-a-GCST006909	MEGASTROKE	Binary	5,386 / 406,111	EUR	M/F	29531354	2018
IS	IEU OpenGWAS	ebi-a-GCST006908	MEGASTROKE	Binary	34,217 / 406,111	EUR	M/F	29531354	2018
AF	IEU OpenGWAS	ebi-a-GCST006061	AFGen, BroadAF, and UKBB	Binary	55,114 / 482,295	EUR	M/F	29892015	2018
Blood lipids									
TG	Neale Lab (R2)	30870_irnt	UKBB	Continuous	343,992	EUR	M/F	NA	2018
TC	Neale Lab (R2)	30690_irnt	UKBB	Continuous	344,278	EUR	M/F	NA	2018
LDL	Neale Lab (R2)	30780_irnt	UKBB	Continuous	343,621	EUR	M/F	NA	2018
HDL	Neale Lab (R2)	30760_irnt	UKBB	Continuous	315,133	EUR	M/F	NA	2018
Apo B	Neale Lab (R2)	30640_irnt	UKBB	Continuous	342,590	EUR	M/F	NA	2018
Apo A	Neale Lab (R2)	30630_irnt	UKBB	Continuous	313,387	EUR	M/F	NA	2018
Blood Pressure									
DBP	Neale Lab (R2)	4079_irnt	UKBB	Continuous	340,162	EUR	M/F	NA	NA
SBP	Neale Lab (R2)	4080_irnt	UKBB	Continuous	340,159	EUR	M/F	NA	NA

Anthropometric Measure									
BMI	Neale Lab (R2)	21001_irnt	UKBB	Continuous	359,983	EUR	M/F	NA	NA
Inflammatory Marker									
IL-6	IEU OpenGWAS	ebi-a-GCST90012005	11 EUR cohorts	Continuous	21,758	EUR	M/F	33067605	2020

AF, atrial fibrillation; Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; BMI, body mass index; CARDIoGRAMplusC4D, Coronary ARtery DIsease Genome wide Replication and Meta-analysis plus The Coronary Artery Disease Genetics; CES, cardioembolic ischemic stroke; CHD, coronary heart disease; DBDS, Danish Blood Donor Study; DBP, diastolic blood pressure; EUR, European; Fe, iron; HDL, high density lipoprotein cholesterol; HUNT, Trøndelag Health Study; IL-6, interleukin-6; IS, ischemic stroke (all-types); LAS, large artery atherosclerotic ischemic stroke; LDL, low density lipoprotein cholesterol; M/F, males/females; MGI, Michigan Genomics Initiative; SBP, systolic blood pressure; SVS, small vessel ischemic stroke; TC, total cholesterol; TG, triglycerides; TIBC, total iron binding capacity; TSAT, transferrin saturatiob; UKBB, UK Biobank

Table 2. Univariate two-sample Mendelian randomization analyses evaluating the associations of genetically predicted iron status and cardiovascular disease outcomes.

Outcome	Exposure	MR method	N SNPs	OR [95 % CI]	P-effect	P-pleiotropy*
CHD	TSAT	IVW	15	0.92 [0.83, 1.03]	0.17	0.0003
		MR Egger	15	0.88 [0.77, 1.02]	0.11	0.33
		WM	15	0.91 [0.84, 0.99]	0.02	-
		MR-PRESSO	14	0.91 [0.85, 0.99]	0.04	-
	Serum Iron	IVW	12	0.89 [0.81, 0.98]	0.02	0.12
		MR Egger	12	0.87 [0.75, 1.00]	0.07	0.56
		WM	12	0.89 [0.82, 0.98]	0.02	-
	TIBC	IVW	15	1.13 [1.03, 1.24]	0.01	0.23
		MR Egger	15	1.08 [0.96, 1.20]	0.22	0.14
		WM	15	1.10 [1.00, 1.21]	0.05	-
		MR-PRESSO	14	1.13 [1.03, 1.24]	0.03	-
	Ferritin	IVW	35	0.92 [0.80, 1.05]	0.23	0.04
		MR Egger	35	0.79 [0.61, 1.02]	0.07	0.17
		WM	35	0.84 [0.71, 1.00]	0.05	-
		MR-PRESSO	33	0.90 [0.79, 1.02]	0.11	-
	IS	TSAT	IVW	14	1.03 [0.93, 1.13]	0.63
MR Egger			14	1.04 [0.92, 1.18]	0.56	0.71
WM			14	1.04 [0.96, 1.11]	0.35	-
MR-PRESSO			12	1.02 [0.97, 1.08]	0.45	-
Serum Iron		IVW	12	1.04 [0.91, 1.18]	0.60	0.002
		MR Egger	12	1.03 [0.86, 1.25]	0.74	0.96
		WM	12	1.03 [0.94, 1.14]	0.49	-

		MR-PRESSO	11	1.02 [0.93, 1.13]	0.64	-
		IVW	14	0.96 [0.89, 1.03]	0.25	0.63
	TIBC	MR Egger	14	0.96 [0.88, 1.05]	0.39	0.98
		WM	14	0.95 [0.88, 1.04]	0.26	-
		IVW	34	1.01 [0.88, 1.16]	0.85	0.16
	Ferritin	MR Egger	34	1.01 [0.77, 1.33]	0.95	0.97
		WM	34	1.06 [0.87, 1.28]	0.57	-
		IVW	14	1.17 [1.03, 1.33]	0.02	0.36
	TSAT	MR Egger	14	1.12 [0.95, 1.32]	0.19	0.42
		WM	14	1.14 [0.99, 1.31]	0.07	-
		IVW	12	1.21 [1.02, 1.44]	0.03	0.23
	Serum Iron	MR Egger	12	1.13 [0.89, 1.45]	0.34	0.44
		WM	12	1.17 [0.97, 1.41]	0.09	-
CES		IVW	14	0.81 [0.69, 0.94]	0.006	0.48
	TIBC	MR Egger	14	0.84 [0.70, 1.01]	0.09	0.43
		WM	14	0.83 [0.70, 0.98]	0.03	-
		IVW	34	1.05 [0.79, 1.40]	0.72	0.04
	Ferritin	MR Egger	34	1.47 [0.84, 2.57]	0.18	0.18
		WM	34	1.38 [0.97, 1.97]	0.08	-
		IVW	14	1.03 [0.85, 1.24]	0.77	0.06
	TSAT	MR Egger	14	1.15 [0.92, 1.43]	0.25	0.13
		WM	14	1.10 [0.92, 1.31]	0.30	-
		IVW	12	1.01 [0.78, 1.32]	0.92	0.02
	Serum Iron	MR Egger	12	1.18 [0.84, 1.66]	0.37	0.23
		WM	12	1.03 [0.81, 1.31]	0.80	-
SVS		IVW	14	0.88 [0.73, 1.05]	0.15	0.38
	TIBC	MR Egger	14	0.83 [0.67, 1.03]	0.12	0.40

		WM	14	0.87 [0.72, 1.04]	0.12	-
		IVW	34	1.05 [0.80, 1.36]	0.75	0.66
	Ferritin	MR Egger	34	1.08 [0.62, 1.87]	0.79	0.89
		WM	34	1.18 [0.80, 1.73]	0.41	-
		IVW	14	0.86 [0.67, 1.10]	0.22	0.006
	TSAT	MR Egger	14	0.86 [0.62, 1.18]	0.36	0.99
		WM	14	0.84 [0.70, 1.00]	0.05	-
		MR-PRESSO	13	0.87 [0.70, 1.08]	0.23	-
		IVW	12	0.82 [0.61, 1.12]	0.21	0.009
	Serum Iron	MR Egger	12	0.86 [0.55, 1.33]	0.51	0.79
		WM	12	0.82 [0.65, 1.04]	0.10	-
LAS		IVW	14	1.23 [1.07, 1.40]	0.003	0.96
	TIBC	MR Egger	14	1.16 [0.91, 1.48]	0.24	0.45
		WM	14	1.19 [0.95, 1.50]	0.12	-
		IVW	34	0.83 [0.60, 1.16]	0.29	0.20
	Ferritin	MR Egger	34	0.74 [0.38, 1.46]	0.39	0.70
		WM	34	0.75 [0.48, 1.18]	0.21	-
		IVW	11	1.07 [0.92, 1.24]	0.37	2.85x10 ⁻¹⁷
	TSAT	MR Egger	11	1.00 [0.83, 1.19]	0.96	0.23
		WM	11	1.07 [1.00, 1.13]	0.04	-
		MR-PRESSO	8	1.09 [1.01, 1.17]	0.047	-
		IVW	11	1.09 [0.90, 1.31]	0.39	1.46x10 ⁻¹⁷
	Serum Iron	MR Egger	11	1.00 [0.75, 1.21]	0.72	0.16
		WM	11	1.05 [0.96, 1.15]	0.30	-
		MR-PRESSO	8	1.14 [1.02, 1.27]	0.046	-
AF		IVW	13	0.92 [0.85, 1.00]	0.05	0.01
	TIBC	MR Egger	13	0.92 [0.83, 1.02]	0.12	0.87

	WM	13	0.93 [0.87, 0.99]	0.02	-
	IVW	33	1.00 [0.88, 1.13]	0.99	0.0005
Ferritin	MR Egger	33	1.08 [0.84, 1.40]	0.54	0.48
	WM	33	1.01 [0.88, 1.16]	0.90	-

**P*-pleiotropy value for IVW method represents the Cochran's *Q* test and for the MR-Egger method represents the Egger-intercept test.

MR-PRESSO outlier-corrected estimates are presented when outliers were detected.

AF, atrial fibrillation; CES, cardioembolic ischemic stroke; CHD, coronary heart disease; IS, ischemic stroke (all-cause); IVW, inverse-variance weighted method under multiplicative random-effects; LAS, large artery atherosclerotic ischemic stroke; MR-PRESSO, Mendelian randomization pleiotropy residual sum and outlier test; SVS, small vessel ischemic stroke; TIBC, total iron binding capacity; TSAT, transferrin saturation; WM, weighted median.

Table 3. Indirect effects reported as log odds ratio of iron status on cardioembolic stroke via selected mediators.

E → M → O	Indirect effect	SE	95% CI	% of total effect mediated
TSAT-DBP-CES	0.014	0.006	0.004, 0.028	8.8
TSAT-BMI-CES	-0.002	0.002	-0.006, 0.002	1.3
TSAT-LDL-CES	0.001	0.008	-0.014, 0.016	0.6
TSAT-TC-CES	0.001	0.007	-0.013, 0.015	0.6
TSAT-TG-CES	0	0.002	-0.003, 0.004	0
TSAT-ApoB-CES	0.001	0.006	-0.011, 0.013	0.6
TSAT-ApoA-CES	-0.002	0.002	-0.006, 0	1.3
SI-DBP-CES	0.014	0.007	0.003, 0.029	7.1
SI-BMI-CES	0	0.002	-0.006, 0.004	0
SI-LDL-CES	0.001	0.008	-0.018, 0.016	0.5
SI-TC-CES	0.001	0.008	-0.015, 0.018	0.5
SI-TG-CES	0	0.002	-0.004, 0.004	0
SI-ApoB-CES	0.002	0.007	-0.013, 0.016	1.0
SI-ApoA-CES	-0.003	0.002	-0.009, 0	1.5
TIBC-DBP-CES	-0.015	0.006	-0.028, -0.005	8.0
TIBC-BMI-CES	0.003	0.002	0.000, 0.007	1.6
TIBC-LDL-CES	0	0.008	-0.015, 0.015	0
TIBC-TC-CES	-0.001	0.007	-0.015, 0.013	0.5
TIBC-TG-CES	0	0.001	-0.003, 0.002	0
TIBC-ApoB-CES	0	0.007	-0.013, 0.013	0
TIBC-ApoA-CES	0.002	0.001	0, 0.005	1.1


The indirect effect is reported as the log odds ratio.

The standard error (SE) and 95% CI for the for the indirect effect was calculated using the delta method. The SE was calculated as: $\sqrt{EM \beta^2 x MO SE^2 + MO \beta^2 x EM SE^2}$.

The percent of the total effect mediated was calculated as the estimated indirect effect divided by the total effect from univariate MR x 100.


Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; BMI, body mass index; CES, cardioembolic ischemic stroke; DBP, diastolic blood pressure; E → M → O, exposure → mediator → outcome; LDL, low density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; TIBC; total iron binding capacity; TSAT, transferrin saturation; SI, serum iron.

Figure 1. Study design and workflow.



CVD, cardiovascular disease; Fe, iron; IVW, inverse variance weighted; MR, Mendelian Randomization; MR-PRESSO, Mendelian randomization pleiotropy residual sum and outlier test; MVMR, multivariate mendelian randomization.


Figure 2. Associations between genetically predicted iron status and cardioembolic ischemic stroke using univariate and multivariate Mendelian randomization.



MR estimates presented as odds ratio (OR) and 95% confidence intervals (CI) per 1-SD unit increase in the Fe exposure.

Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; BMI, body mass index; CES, cardioembolic ischemic stroke; DBP, diastolic blood pressure; LDL, low density lipoprotein cholesterol; MVMR, multivariate Mendelian randomization; TC, total cholesterol; TG, triglycerides; UVMR, univariate Mendelian randomization.

Figure 3. Associations between genetically predicted iron status and atherosclerotic cardiovascular disease outcomes using univariate and multivariate Mendelian randomization.



MR estimates presented as odds ratio (OR) and 95% confidence intervals (CI) per 1-SD unit increase in the Fe exposure.

Apo-A, apolipoprotein-A; Apo-B, apolipoprotein-B; BMI, body mass index; DBP, diastolic blood pressure; CHD, coronary heart disease; LAS, large artery atherosclerotic ischemic stroke; LDL, low density lipoprotein cholesterol; MVMR, multivariate Mendelian randomization; TC, total cholesterol; TG, triglycerides; UVMR, univariate Mendelian randomization.